Sentences with phrase «cell tumor treatment»

Rocky Coal Mountain Boxer Pennsylvania Diagnosis: Mast Cell Tumor Treatment: Surgical Removal

Daisy California Chihuahua Pug mix Diagnosis: Mast Cell Tumors Treatment: Oncology Care Application Accepted: 01/26/17

Rigsby New York Pit Bull Diagnosis: Cranial Cruciate Ligament Rupture & Mast Cell Tumors Treatment: Surgery

Not exact matches

Immunotherapy differs from more traditional cancer treatments, such as surgery (cutting malignant cells out of the body), chemotherapy and radiation (poisoning the deadly mutants), and even the newer, more precise molecular drugs that attempt to jam the protein signals that tell tumor cells to keep dividing and conquering.

CAR - T cell therapy is a form of immunotherapy, a rapidly developing cancer treatment that uses patients» own immune cells to attack tumors.

Chicago, GenomeWeb — A new study by researchers from Memorial Sloan Kettering Cancer Center has demonstrated the predictive power of an AR - V7 protein expression test using Epic Sciences» non-EPCAM-based circulating tumor cell detection platform, which could help guide treatment decisions for men with metastatic castration - resistant prostate cancer.

«An index measures similarity between cancer cells and pluripotent stem cells: The new methodology measures tumor aggressiveness and the risk of relapse, helping doctors plan treatment.»

In some mice, the scientists removed tumors after they were established, and injected treatment cells into the cavity.

«Used in cancer therapy, this process could increase the impact of a treatment by heating the cancer cells while introducing the drug compound into the tumor.»

CCG is also developing cell lines that are cultured to represent tumor behavior in vivo, and computational methods that will help researchers understand tumor behavior and apply the resulting data to diagnoses, treatments, and cures.

Even before treatment, cancer patients in the study had a small number of infection - and tumor - fighting T cells that target these unusual proteins, the researchers found.

«This combinational treatment also was well tolerated and enhanced the number of CD8 T cells at the tumor site.

Inspired by his own bout of leukemia to try to find a better cancer treatment, retired broadcasting station owner Kanzius guessed that as an alternative to chemotherapy, he could inject tumors with metal ions, then use radio waves to heat the metal and destroy cancerous cells.

These results suggest GSK2636771 treatment can «synergize» with OX40 agonist antibodies to augment effector functions of tumor - reactive T cells.»

Pre-clinical studies have shown that ALT - 803 activates the immune system to mobilize lymphocytes against tumor cells and could potentially serve as an important component in combination treatments.

Conventional, high - dose chemotherapy treatments can cause the fibroblast cells surrounding tumors to secrete proteins that promote the tumors» recurrence in more aggressive forms, researchers at Taipei Medical University and the National Institute of Cancer Research in Taiwan and University of California, San Francisco, have discovered.

Seven to eight weeks after the tumor was established, each mouse received one intravenous injection of GD2 CAR - T cells or, as a control treatment, an injection of CAR - T cells that react to a different target.

«Our work strongly supports that cancer stem cells are the main source of growth in these tumors and, as such, should be considered promising targets for treatment,» says Mario Suvà, MD, PhD, of the MGH Department of Pathology, co-senior author of the Nature paper.

The activity of four transcription factors — proteins that regulate the expression of other genes — appears to distinguish the small proportion of glioblastoma cells responsible for the aggressiveness and treatment resistance of the deadly brain tumor.

In the mice that received GD2 CAR - T cells, the DIPG tumors were undetectable after 14 days, while mice receiving the control treatment had no tumor regression.

Artist's conception of nanoparticle - carrying immune cells that target tumors and release drug - loaded nanoparticles for cancer treatment.

Pembrolizumab, or pembro, an immunotherapy drug that unmasks cancer cells and allows the body's own immune system to help destroy tumors, appears to be safe in treating lung cancers, according to a study by Cancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arizona.

«Considering that PDPN is associated with poor prognosis in GBM, CAR T - cell therapy that targets this protein is promising for treatment of patients with relapsed or resistant tumors following first - line chemotherapy,» says Toshihiko Wakabayashi, a coauthor and the chair of Department of Neurosurgery Nagoya University School of Medicine.

By releasing the brakes that tumor cells place on the immune system, researchers are developing a new generation of more powerful treatments against malignancy

Drugs That Ramp Up the Immune System against Tumor Cells are Revolutionizing Cancer Treatment

These findings also have implications for treatment of cancer and other disorders, such as obesity, in which M2 macrophage cells play a regulatory role in tumor growth and fat deposition.

According to this theory, tumor cells tend to «forget» the tissue from which they originated as the disease progresses, acquiring an undifferentiated phenotype associated with heightened aggressiveness and treatment resistance.

To acquire new insights into the biology and possible therapy of these tumors, Feigin et al. looked for aberrant expression of G protein — coupled receptors, cell signaling proteins that have been successfully targeted for treatment of other disorders such as depression.

These modifications contribute to a tumor's ability to grow indefinitely, as well as making tumor cells drug resistant and capable of surviving treatments intended to kill them.

«An index measures similarity between cancer cells and pluripotent stem cells: The new methodology measures tumor aggressiveness and the risk of relapse, helping doctors plan treatment.»

That allowed tumor cells to survive gemcitabine treatment in lab dishes and mouse studies, Leore Geller of the Weizmann Institute of Science in Rehovot, Israel, and colleagues discovered.

Although changes in treatment methodology still have to be studied, Dr. Cripe believes it may be that the timing of various treatments is what matters, and that perhaps initially suppressing immunity could allow the virus to infect a large number of tumor cells before relieving the immunosuppression to allow the body's own T cells to fight off the tumor.

Compared to a control (left), epalrestat treatment (right) reduces the number of metastatic tumors (arrowheads) in the lungs of mice injected with human basal - like breast cancer cells.

However, some human tumor cells may also be hard to infect with viral therapies, Dr. Cripe reasoned, and knowing how cells respond in those situations could also be important to improving cancer treatments.

The development of targeted therapies has significantly improved the survival of melanoma patients over the last decade; however, patients often relapse because many therapies do not kill all of the tumor cells, and the remaining cells adapt to treatment and become resistant.

For each patient, the suitable combination treatment could then be designed, which, in the first step, would turn the variety of different tumor cells into a mass of cancer cells of the same type.

Therefore, chloroquine can nip the metastatic spreading of cancer cells in the bud, which is the most important therapeutic goal in any tumor treatment.»

Now a team of researchers in China has developed a new microfluidic chip that can quickly and efficiently segregate and capture live circulating tumor cells (CTCs) from a patient's blood, with potential applications for cancer screenings and treatment assessments.

«This is a treatment that, rather than targeting cancer cells themselves, targets the immune response, reactivating the T cells in the neighborhood of the tumor cells,» Shipp remarked.

However, the cancer cells of individual other tumor facets of the same patient survived the treatment and were even able to reproduce much more intensively.

The discovery of an unexpected biochemical link within tumor cells should lead to clinical trials for experimental drug treatments that indirectly target myc and that already are being evaluated in human studies, the researchers said.

With standard treatments of surgery, chemotherapy and radiation, the median survival time is only 14.6 months, and improvement will only come with the ability to kill tumor cells resistant to standard treatments, according to Alfredo Quiñones - Hinojosa, M.D., a professor of neurosurgery at the Johns Hopkins University School of Medicine and a member of the research team.

Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression - free survival.

Proliferation of such cells, which tend to resist chemotherapy and help tumors spread, are considered a major roadblock to successful cancer treatment.

«FDG PET shows tumor DNA levels in blood are linked to NSCLC aggressiveness: Insights derived from FDG PET could improve treatment selection for patients with advanced non-small cell lung cancer.»

Treatment with an investigational CAR T - cell therapy induced complete remission of a brain metastasis of the difficult - to - treat tumor diffuse large - B - cell lymphoma (DLBCL), which had become resistant to chemotherapy — the first report of a response to CAR T - cells in a central nervous system lymphoma.

Research on metastatic colorectal cancer and sarcoma, however, suggests a potential benefit from adding local therapy — treatment directed specifically at the tumor cells — to the standard approach of systemic therapy.

Metastasis, or cancer spread by the formation of tumors at new sites, is generally what makes cancers deadly because surgery and other treatments are unlikely to find and destroy every cancer cell.

They find that the cells can remain dormant during chemotherapy that kills off most of the cancer and can give rise to new tumors once the drug treatment stops.

«By understanding how stress accelerates invasion in aggressive breast tumor cells, this work will inform future studies into whether beta - blockers could be a useful adjuvant therapy in the treatment of some aggressive breast cancers.»